etabolic Endocrine Education Foundation (MEEF) Lindero Canyon Dr Suite # 380 0ak Park, CA 91377

ORG US POSTAGE PAID VAN NUYS, CA PERMIT # 659 NONPROFIT

# CME Symposium 22 IN ASSOCIATION WITH THE WCIRDC



2.0

The Complications of DCRM-Diabetes & **CardioRenalMetabolic** Patient

> Thursday, December 12, 2024 7:30 pm - 9:30 pm PST **Hilton Universal City Hotel** Los Angeles, California **DINNER WILL BE SERVED**

## All content available ON-DEMAND for ONE YEAR following the meeting.

This is a CME Symposium Supported by an Educational Grant from AstraZeneca Free for all 22nd WCIRDC attendees. Register online: www.wcir.org/registration This CME Symposium will be available and FREE for ONE year following the meeting.

Provided By:

Register Online: www.heartindiabetes.com/registration

**☆**PESI

CME MOC ACCREDITED

Administered By:





## THE COMPLICATIONS OF THE DCRM- DIABETES & CARDIORENALMETABOLIC - PATIENT

CHAIRS: Yehuda Handelsman, MD • Stephen J. Greene, MD

7:30 – 9:30 pm	Dinner CME Symposium Supported by AstraZeneca
7:30 pm	Dinner and Wine Served
7:45 pm	Introduction & Pre-CME Questions Stephen J. Greene, MD
7:55 pm	Diabetes & CRM Approach to Comorbidities Peter Rossing, MD, DMSc
8:15 pm	Heart Failure & Cardiomyopathy- Addressing Etiologies Michelle M. Kittleson, MD, PhD
8:35 pm	The Treatment of CKD and Heart Failure Circa 2024 Katherine R. Tuttle, MD
8:55 pm	Panel Discussion and Q&A: The Physician's Role in the Proper Diagnosis of DCRM Complications
	Panel: Stephen J. Greene, MD • Michelle M. Kittleson, MD, PhD Peter Rossing, MD, DMSc • Katherine R. Tuttle, MD Moderator: Yehuda Handelsman, MD Post-CME Questions & Concluding Remarks
9:30 pm	Adjourn

### **Program Description**

Comorbidities of Obesity, diabetes namely Cardiorenal metabolic diseases are often not diagnosed or overlooked. Especially Chronic kidney disease (CKD) and heart failure (HF) which are not just under-diagnosed but generally under-treated. Failure to treat these conditions may lead to high risk of hospitalization and death. This satellite symposium will address the pathophysiology of these complications and explore strategies for correctly diagnosing and treating patients with obesity and diabetes who have cardiorenal-metabolic complications. The symposium will address gaps in physicians' knowledge in diagnosing and managing these high risk patients.

### **Learning Objectives**

Upon completion of this CME symposium, participants should be able to:

- Describe the epidemiologic and pathophysiologic connections that link obesity, diabetes and cardiorenal comorbidities
- Understand the etiology of Cardiomyopathy and Heart Failure
- Review the use of SGLT2 inhibitors and in combination with RAS inhibitors, MRAs, and GLP-1 RAs in the management of HF and or CKD
- The Physician's Role in the Proper Diagnosis of DCRM Complications and administration of appropriate treatment of CKD, HF & cardiomyopathy

### **Target Audience**

This educational initiative is designed for cardiologists, nephrologists, endocrinologists, internists, family physicians, and other healthcare professionals interested in the epidemiology, pathophysiology, prevention, and treatment of CKD and HF and prevention of morbidity and mortality.



Yehuda Handelsman, MD, Chair FACP, FNLA, FASPC, FAHA, MACE Medical Director & Principal Investigator The Metabolic Institute of America Chair Scientific Advisory Board DCMi- Diabetes CardioRenal & Metabolism Institute Chair & Program Director 22nd WCIRDC Tarzana, California



Michelle M. Kittleson, MD, PhD Professor of Medicine Director of Education in Heart Failure and Transplantation Smidt Heart Institute, Cedars-Sinai Los Angeles, CA



#### Stephen J. Greene, MD, Chair

Associate Professor of Medicine, Division of Cardiology Co-Director, Duke Heart Failure Medication Titration Clinic Duke Clinical Research Institute Duke University School of Medicine Durham, North Carolina



Katherine R. Tuttle, MD Executive Director for Research, Providence Inland Northwest Health Professor of Medicine, Division of Nephrology and Kidney Research Institute Regional Principal Investigator Institute of Translational Health Sciences University of Washington



Peter Rossing, MD, DMSc Professor Department of Clinical Medicine University of Copenhagen Steno Diabetes Center Copenhagen Herlev, Denmark

### **CME DINNER SYMPOSIUM**

This CME symposium is FREE for 22nd WCIRDC attendees and will stay on-demand for ONE year following the meeting. Learn more: WCIR.ORG/CMEsymposium

> To register for the entire 22nd WCIRDC meeting Please visit: wcir.org/registration

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of PESI Inc., and Metabolic Endocrine Education Foundation (MEEF). PES Inc. is accredited by the ACCME to provide continuing medical education for physicians.

PESI, Inc., designated this live educational activity for a maximum of 2.00 AMA PRA Category 1 Credit(s).

Physicians should only claim credit commensurate with the extent of their participation in the activity.

For information please contact: info@tmioa.com or 818 342 1889

This is a CME Program Supported by an Educational Grant from AstraZeneca

## FACULTY